220 related articles for article (PubMed ID: 29037604)
1. MET Activation and Physical Dynamics of the Metastatic Process: The Paradigm of Cancers of Unknown Primary Origin.
Stella GM; Benvenuti S; Gentile A; Comoglio PM
EBioMedicine; 2017 Oct; 24():34-42. PubMed ID: 29037604
[TBL] [Abstract][Full Text] [Related]
2. MET mutations in cancers of unknown primary origin (CUPs).
Stella GM; Benvenuti S; Gramaglia D; Scarpa A; Tomezzoli A; Cassoni P; Senetta R; Venesio T; Pozzi E; Bardelli A; Comoglio PM
Hum Mutat; 2011 Jan; 32(1):44-50. PubMed ID: 20949619
[TBL] [Abstract][Full Text] [Related]
3. Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
Meagher NS; Schuster K; Voss A; Budden T; Pang CNI; deFazio A; Ramus SJ; Friedlander ML
Gynecol Oncol; 2018 Sep; 150(3):527-533. PubMed ID: 30054102
[TBL] [Abstract][Full Text] [Related]
4. Cancers of unknown primary origin (CUP) are characterized by chromosomal instability (CIN) compared to metastasis of know origin.
Vikeså J; Møller AK; Kaczkowski B; Borup R; Winther O; Henao R; Krogh A; Perell K; Jensen F; Daugaard G; Nielsen FC
BMC Cancer; 2015 Mar; 15():151. PubMed ID: 25885340
[TBL] [Abstract][Full Text] [Related]
5. Mutational profiling of the RAS, PI3K, MET and b-catenin pathways in cancer of unknown primary: a retrospective study of the Hellenic Cooperative Oncology Group.
Pentheroudakis G; Kotteas EA; Kotoula V; Papadopoulou K; Charalambous E; Cervantes A; Ciuleanu T; Fountzilas G; Pavlidis N
Clin Exp Metastasis; 2014 Oct; 31(7):761-9. PubMed ID: 24997156
[TBL] [Abstract][Full Text] [Related]
6. FOXC2 promotes colorectal cancer metastasis by directly targeting MET.
Cui YM; Jiao HL; Ye YP; Chen CM; Wang JX; Tang N; Li TT; Lin J; Qi L; Wu P; Wang SY; He MR; Liang L; Bian XW; Liao WT; Ding YQ
Oncogene; 2015 Aug; 34(33):4379-90. PubMed ID: 25381815
[TBL] [Abstract][Full Text] [Related]
7. MET amplification increases the metastatic spread of EGFR-mutated NSCLC.
Baldacci S; Kherrouche Z; Cockenpot V; Stoven L; Copin MC; Werkmeister E; Marchand N; Kyheng M; Tulasne D; Cortot AB
Lung Cancer; 2018 Nov; 125():57-67. PubMed ID: 30429039
[TBL] [Abstract][Full Text] [Related]
8. A point mutation in the MET oncogene abrogates metastasis without affecting transformation.
Giordano S; Bardelli A; Zhen Z; Menard S; Ponzetto C; Comoglio PM
Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13868-72. PubMed ID: 9391119
[TBL] [Abstract][Full Text] [Related]
9. The matrix environmental and cell mechanical properties regulate cell migration and contribute to the invasive phenotype of cancer cells.
Mierke CT
Rep Prog Phys; 2019 Jun; 82(6):064602. PubMed ID: 30947151
[TBL] [Abstract][Full Text] [Related]
10. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas.
Di Renzo MF; Olivero M; Martone T; Maffe A; Maggiora P; Stefani AD; Valente G; Giordano S; Cortesina G; Comoglio PM
Oncogene; 2000 Mar; 19(12):1547-55. PubMed ID: 10734314
[TBL] [Abstract][Full Text] [Related]
11. MET receptor is overexpressed but not mutated in oral squamous cell carcinomas.
Morello S; Olivero M; Aimetti M; Bernardi M; Berrone S; Di Renzo MF; Giordano S
J Cell Physiol; 2001 Dec; 189(3):285-90. PubMed ID: 11748586
[TBL] [Abstract][Full Text] [Related]
12. lncRNA HOTAIR overexpression induced downregulation of c-Met signaling promotes hybrid epithelial/mesenchymal phenotype in hepatocellular carcinoma cells.
Topel H; Bagirsakci E; Comez D; Bagci G; Cakan-Akdogan G; Atabey N
Cell Commun Signal; 2020 Jul; 18(1):110. PubMed ID: 32650779
[TBL] [Abstract][Full Text] [Related]
13. Targeting the MET oncogene in cancer and metastases.
Stella GM; Benvenuti S; Comoglio PM
Expert Opin Investig Drugs; 2010 Nov; 19(11):1381-94. PubMed ID: 20868306
[TBL] [Abstract][Full Text] [Related]
14. Induction of c-met proto-oncogene expression at the metastatic site.
Imai J; Watanabe M; Sasaki M; Yamaguchi R; Tateyama S; Sugano S
Clin Exp Metastasis; 1999 Jul; 17(5):457-62. PubMed ID: 10651314
[TBL] [Abstract][Full Text] [Related]
15. Prediction of Primary Tumors in Cancers of Unknown Primary.
Søndergaard D; Nielsen S; Pedersen CNS; Besenbacher S
J Integr Bioinform; 2017 Jul; 14(2):. PubMed ID: 28686574
[TBL] [Abstract][Full Text] [Related]
16. Identifying primary site of lung-limited Cancer of unknown primary based on relative gene expression orderings.
Li M; Li H; Hong G; Tang Z; Liu G; Lin X; Lin M; Qi L; Guo Z
BMC Cancer; 2019 Jan; 19(1):67. PubMed ID: 30642283
[TBL] [Abstract][Full Text] [Related]
17. In bone metastasis miR-34a-5p absence inversely correlates with Met expression, while Met oncogene is unaffected by miR-34a-5p in non-metastatic and metastatic breast carcinomas.
Maroni P; Puglisi R; Mattia G; Carè A; Matteucci E; Bendinelli P; Desiderio MA
Carcinogenesis; 2017 May; 38(5):492-503. PubMed ID: 28334277
[TBL] [Abstract][Full Text] [Related]
18. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype.
Kaposi-Novak P; Lee JS; Gòmez-Quiroz L; Coulouarn C; Factor VM; Thorgeirsson SS
J Clin Invest; 2006 Jun; 116(6):1582-95. PubMed ID: 16710476
[TBL] [Abstract][Full Text] [Related]
19. A Review on Cancer of Unknown Primary Origin: The Role of Molecular Biomarkers in the Identification of Unknown Primary Origin.
Yan N; Zhang Y; Guo X; Yuan D; Tian G; Yang J
Methods Mol Biol; 2020; 2204():109-119. PubMed ID: 32710319
[TBL] [Abstract][Full Text] [Related]
20. Activation of Src by c-Met overexpression mediates metastatic properties of colorectal carcinoma cells.
Herynk MH; Zhang J; Parikh NU; Gallick GE
J Exp Ther Oncol; 2007; 6(3):205-17. PubMed ID: 17552361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
